CD44 and acute myeloid leukemia: In vivo administration of an activating mAb specific for CD44 (H90) to NOD/SCID (non-obese diabetic/severe combined immune-deficient) mice, transplanted with human AML cells, considerably inhibited leukemic repopulation, indicating that AML LSCs are directly targeted [70].